Repligen Corporation RGEN
Super Investor & Insider
2
Fondi che lo detengono
#495
Rank consenso
2.9%
% dei portafogli
$182.0M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | 2.08% | Buy | 1,518,805 | $178.9M |
| Wallace Weitz · Weitz Investment Management | 0.21% | Buy | 25,500 | $3.0M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves …
SectorHealthcare
ExchangeNASDAQ
IndustryMedical Instruments & Supplies
CountryUnited States
Employees1,778
TickerRGEN
Statistics
Market Cap$7.58B
Revenue (TTM)$738.3M
Net Income$48.9M
Net Margin6.6%
EPS$0.86
P/E143.51
P/S9.65
P/B3.50
EV/EBITDA54.15
ROE2.5%
Dividend Yield—
Price$134.34
Data: Twelve Data · Revenue = mcap / P/S